Here is a comprehensive overview of endometrioid carcinoma based on authoritative textbook sources:
Endometrioid Carcinoma
Overview
Endometrioid carcinoma is the most common type of endometrial carcinoma, accounting for approximately 80-85% of cases. Most are well-differentiated and microscopically mimic proliferative endometrial glands - the basis of the name. It typically arises in the setting of endometrial hyperplasia and is strongly associated with conditions of unopposed estrogenic stimulation of the endometrium. - Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 933
Risk Factors / Associations
| Factor | Notes |
|---|
| Obesity | Major risk factor; particularly high in Western populations |
| Hypertension | Commonly co-occurs |
| Type 2 Diabetes | Co-occurs via obesity link |
| Unopposed estrogen | Exogenous or endogenous excess |
| Nulliparity | |
| Anovulatory cycles | |
| Lynch syndrome | ~3-5% of endometrial cancers; associated DNA mismatch repair defects |
Peak incidence is in postmenopausal females aged 55-65; the incidence in younger females is increasing.
Pathogenesis & Molecular Alterations
Development follows stepwise acquisition of mutations in tumor suppressor genes and oncogenes. A hallmark is increased signaling through the PI3K/AKT pathway:
| Gene | Frequency | Role |
|---|
| PTEN (tumor suppressor) | 30-80% | Loss of function; most common mutation |
| PIK3CA (oncogene) | ~40% | Activating mutation; encodes catalytic subunit of PI3K |
| KRAS | ~25% | Activating mutation; also stimulates PI3K/AKT |
| ARID1A | ~1/3 | Loss of function; chromatin regulator; also mutated in ovarian endometrioid/clear cell |
| DNA mismatch repair (MLH1) | ~20% sporadic | Epigenetic silencing via promoter hypermethylation; prevalent in Lynch syndrome |
| DNA polymerase ε (POLE) | <10% | "Ultramutated" phenotype; highest somatic mutation burden of any cancer |
PI3K/AKT signaling also augments estrogen receptor-dependent gene expression, linking molecular and hormonal pathogenesis. - Robbins p. 933
Morphology
Grossly, endometrioid carcinoma can present as a localized polypoid mass or diffusely involve the endometrial lining.
Fig. 22.24: (A) Fungating mass in the fundus. (B) Grade 1 - well-differentiated glands, no intervening stroma. (C) Grade 2 - glands mixed with solid areas (≤50% solid). (D) Grade 3 - predominantly solid (>50% solid). - Robbins, Cotran & Kumar
Histologic Grading (FIGO)
| Grade | Description |
|---|
| Grade 1 (Low-grade) | Well-formed glands only; <5% solid non-squamous growth |
| Grade 2 (Low-grade) | Well-formed glands + solid areas (6-50% solid) |
| Grade 3 (High-grade) | >50% solid growth pattern |
- Grades 1 and 2 are often combined into a low-grade binary category; Grade 3 is high-grade.
- Up to 20% contain foci of squamous differentiation (adenoacanthoma when benign-appearing squamous elements are present). Grading is based on the glandular component only.
- Tumors with POLE mutations or DNA mismatch repair defects often show large numbers of infiltrating T cells (tumor-infiltrating lymphocytes).
Variants of Endometrioid Carcinoma
| Variant | Features |
|---|
| Villoglandular | ~2%; papillary arrangement along fibrovascular stalks; always well-differentiated; good prognosis |
| Secretory | ~1%; early postmenopausal; intracytoplasmic vacuoles like secretory endometrium; excellent prognosis; must be distinguished from clear cell carcinoma |
| With squamous differentiation | Up to 20%; grading based on glandular component alone |
Spread
- Myometrial invasion (depth is the key staging parameter)
- Direct extension to adjacent structures (broad ligaments, cervix, adnexa)
- Regional lymph node involvement
- Distant metastases (lungs, liver, bone) in late stages
Clinical Features
- Postmenopausal vaginal bleeding - the hallmark symptom and often leads to early detection
- May be asymptomatic early in course
- Diagnosis by endometrial biopsy, pipelle sampling, or hysteroscopic biopsy + histologic examination
- At diagnosis, Lynch syndrome testing (DNA mismatch repair) should be performed - 3-5% of cases have Lynch syndrome, conferring high risk for colorectal cancer
FIGO Staging (Surgical-Pathological)
| Stage | Description | MRI Finding |
|---|
| Ia | Confined to corpus; <50% myometrial invasion | Signal extends into <50% myometrium |
| Ib | Confined to corpus; ≥50% myometrial invasion | Signal extends into ≥50% myometrium |
| II | Cervical stromal invasion (not beyond uterus) | Disruption of low-signal cervical stroma |
| IIIa | Serosa/adnexa involved | Irregular outer uterine contour |
| IIIb | Vaginal/parametrial involvement | Loss of hypointense vaginal wall |
| IIIc1/IIIc2 | Pelvic/para-aortic lymph node metastasis | Nodes >1 cm or abnormal signal |
| IVa | Bladder/bowel mucosa invasion | Disruption of bladder/rectal mucosa signal |
| IVb | Distant metastases | Tumor in distant sites |
MRI is the key imaging modality for staging - it accurately assesses depth of myometrial invasion, cervical stromal invasion, and pelvic organ involvement. - Grainger & Allison's Diagnostic Radiology, p. 872
Prognosis
| Stage/Grade | 5-Year Survival |
|---|
| Stage I (grade 1/2) | ~90% |
| Stage I (grade 3) | ~75% |
| Stage II-III | ≤50% |
In the USA, ~80% of tumors are Stage I, well- or moderately differentiated at presentation - the reason for the generally favorable prognosis.
Treatment
| Scenario | Approach |
|---|
| Localized endometrioid | Total abdominal hysterectomy + bilateral salpingo-oophorectomy (TAH + BSO) ± adjuvant radiotherapy |
| Adjuvant radiation | Reduces local recurrence in higher-risk early-stage disease |
| Spread beyond uterus | Chemotherapy added |
| Hypermutated tumors (MSI-H / POLE) | Immune checkpoint inhibitors (e.g., pembrolizumab) |
| HER2-amplified (25-30% of cases) | HER2-targeted therapy |
Endometrioid Carcinoma vs. Serous Carcinoma (Key Comparison)
| Feature | Endometrioid | Serous |
|---|
| Frequency | 80-85% | ~15% |
| Hormone association | Estrogen-driven | Estrogen-independent |
| Precursor | Endometrial hyperplasia | Endometrial atrophy |
| Key mutation | PTEN, PIK3CA, KRAS | TP53 (>90%) |
| Grade | Usually low-grade | High-grade |
| Prognosis | Generally favorable | Poor (5-year survival 18-27%) |
| Age at presentation | Younger (55-65) | Older (~10 yrs more) |
Endometrioid Carcinoma of the Ovary (Bonus)
Endometrioid carcinoma also accounts for approximately 20% of all ovarian cancers. About 15-30% coexist with endometriosis, and ~15-20% coexist simultaneously with uterine endometrioid carcinoma. The peak incidence is a decade earlier than that of uterine endometrioid carcinomas associated with endometriosis. - Robbins p. 3296